Previous Article | Next Article 
Journal of Virology, October 1998, p. 8191-8197, Vol. 72, No. 10
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
The Human Cytomegalovirus UL74 Gene Encodes the
Third Component of the Glycoprotein H-Glycoprotein L-Containing
Envelope Complex
Mary T.
Huber and
Teresa
Compton*
Program in Cellular and Molecular Biology and
Department of Medical Microbiology and Immunology, University of
Wisconsin
Madison, Madison, Wisconsin 53706-1532
Received 15 May 1998/Accepted 6 July 1998
 |
ABSTRACT |
The human cytomegalovirus (HCMV) gCIII envelope complex is composed
of glycoprotein H (gH; gpUL75), glycoprotein L (gL; gpUL115), and a
third, 125-kDa protein not related to gH or gL (M. T. Huber and T. Compton, J. Virol. 71:5391-5398, 1997; L. Li, J. A. Nelson, and W. J. Britt, J. Virol. 71:3090-3097, 1997). Glycosidase
digestion analysis demonstrated that the 125-kDa protein was a
glycoprotein containing ca. 60 kDa of N-linked oligosaccharides on a
peptide backbone of 65 kDa or less. Based on these biochemical
characteristics, two HCMV open reading frames, UL74 and TRL/IRL12, were
identified as candidate genes for the 125-kDa glycoprotein. To identify
the gene encoding the 125-kDa glycoprotein, we purified the gCIII complex, separated the components by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, and subjected gH and the
125-kDa glycoprotein to amino acid microsequence analysis.
Microsequencing of an internal peptide derived from purified 125-kDa
glycoprotein yielded the amino acid sequence LYVGPTK. A FASTA search
revealed an exact match of this sequence to amino acids 188 to 195 of
the predicted product of the candidate gene UL74, which we have
designated glycoprotein O (gO). Anti-gO antibodies reacted in
immunoblots with a protein species migrating at ca. 100 to 125 kDa in
lysates of HCMV-infected cells and with 100- and 125-kDa protein
species in purified virions. Anti-gO antibodies also immunoprecipitated
the gCIII complex and recognized the 125-kDa glycoprotein component of
the gCIII complex. Positional homologs of the UL74 gene were found in
other betaherpesviruses, and comparisons of the predicted products of
the UL74 homolog genes demonstrated a number of conserved biochemical
features.
 |
INTRODUCTION |
The envelope glycoproteins of the
herpesviruses play multiple critical roles in the viral life cycle,
including attachment, penetration, cell-to-cell spread, and envelopment
and maturation of nascent viral particles. To understand the life
cycles of these complex viruses, it is necessary to have a thorough
knowledge of the structures and functions of the envelope
glycoproteins. Biochemical studies of human cytomegalovirus (HCMV)
virions revealed that the viral envelope contains at least 10 glycoproteins, many of which are organized into three predominant
high-molecular-weight, disulfide-bonded complexes designated gCI, gCII,
and gCIII (23). Given the resolution of earlier analyses and
the large coding capacity of HCMV (9), it is very likely
that other proteins are also present in the viral envelope. To date,
however, only six virion envelope glycoproteins have been mapped to the
viral genome: gp48 (UL4) (8), GCR33 (UL33) (37),
glycoprotein B (gB; UL55) (4, 12, 36), glycoprotein H (gH;
UL75) (13, 41, 44), glycoprotein M (gM; UL100) (1, 27,
32), and glycoprotein L (gL; UL115) (24, 28, 33, 50).
The gH-gL complexes of herpesviruses, including HCMV, have been
implicated in viral fusion events, including entry and cell-to-cell spread (18-20, 29, 30, 38, 41, 42, 46, 47). To understand the specific molecular function(s) of HCMV gH-gL, it is necessary to
define the structural organization of these glycoproteins as they exist
in the virus. Earlier studies demonstrated that the 240-kDa gCIII
envelope complex contained the gH and gL homologs of HCMV (13, 23,
24, 33, 41, 44). However, coexpression of gH and gL in
recombinant systems did not reconstitute gCIII, suggesting that the
gCIII complex contained other gene products which were distinct from gH
and gL (24, 33). Detailed characterization of gCIII clearly
demonstrated that a 125- to 145-kDa protein was present in gCIII from
HCMV-infected cells and purified virions (23, 24, 33). The
125-kDa protein was shown to be antigenically and structurally
unrelated to either gH or gL, explaining the lack of gCIII
reconstitution by coexpression of gH and gL and suggesting that a third
HCMV gene product was contained in the complex (24, 33).
In this study, we report that the 125-kDa protein is encoded by the
HCMV UL74 gene. The biochemical features of the 125-kDa protein
revealed it was a glycoprotein and suggested the UL74 open reading
frame (ORF) as a possible candidate gene. Amino acid microsequencing of
the purified 125-kDa glycoprotein confirmed that this glycoprotein was
the product of the UL74 gene. Additionally, an anti-UL74 antibody
immunoprecipitated the 240-kDa gCIII complex and specifically
recognized the 125-kDa glycoprotein component of gCIII. Together, these
data corroborate that the HCMV UL74 gene product, which we have
designated glycoprotein O (gO), is the third glycoprotein component of
the gCIII complex. Interestingly, the HCMV gO gene has positional
homologs in the betaherpesvirus subfamily, and a comparison of the
predicted products of the gO homolog genes revealed a number of shared
biochemical features.
 |
MATERIALS AND METHODS |
Cells, viruses, and antibodies.
Immortalized fibroblast (IF)
cells were cultured as previously described (10). The AD169
strain of HCMV was grown and titered as previously described
(10). Gradient-purified virions were isolated as previously
described (11). Monoclonal antibodies 14-4b (5)
and AP865 (51), generously supplied by W. Britt, and
polyclonal antibody 26388, kindly provided by A. Minson, were described
previously (24).
Immunoblotting and immunoprecipitations.
Immunoblotting and
immunoprecipitations were performed essentially as previously described
(24). In brief, proteins were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (with or without
reducing agents) and electrotransferred to nitrocellulose (Millipore)
for immunoblotting. Primary antibodies were detected with horseradish
peroxidase (HRP)-conjugated goat anti-mouse or anti-rabbit antibodies
(Pierce). Renaissance Western blot chemiluminesence reagent (NEN) was
used to detect the peroxidase conjugates. For immunoprecipitations, IF
cells were radiolabeled with 50 µCi of
[35S]methionine-cysteine (NEN)/ml for 16 h.
Radioimmunoprecipitation assay (RIPA) (24) cell lysates were
precleared with protein G (formalin-killed cell suspension; Sigma) and
supplemented with 0.5% bovine serum albumin. The precipitating
antibody was added to the lysates, and antibody-antigen complex was
recovered with immobilized protein A (Pierce). The protein A pellets
were washed extensively with RIPA lysis buffer and resuspended in
SDS-PAGE sample buffer (with or without reducing agents) in preparation for SDS-PAGE. Resultant gels were dried and imaged via a GS-525 Molecular Imager (Bio-Rad).
N-Glycosidase F digestion of biotinylated
proteins.
IF cells were infected with HCMV at a multiplicity of
infection (MOI) of 3. At 4 days postinfection, infected cell monolayers were washed with PBS-MC (phosphate-buffered saline [PBS] supplemented with 1 mM MgCl2 and 0.1 mM CaCl2). EZ-link
sulfo-NHS-LC biotin (Pierce) in PBS-MC (2 mg/ml) was added to the
cells, which were then incubated at 37°C for 1 h. The biotin
solution was removed, and the cells were washed extensively with
PBS-MC. To quench the biotinylation reaction, 10 mM glycine in PBS-MC
was added to the cells for 10 min at 37°C. The glycine solution was
removed, and the cells were washed extensively with PBS-MC.
N-Glycosidase F (Boehringer Mannheim) digestions were
performed as instructed by the manufacturer. Briefly,
immunoprecipitated proteins recovered by immobilized protein A were
heated at 95°C for 3 min in a PBS solution containing 0.45% SDS and
90 mM
-mercaptoethanol. After centrifugation to remove the
immobilized protein A, the denatured protein solution was diluted
twofold with PBS and made 50 mM in EDTA and 1% in Nonidet P-40.
Samples were digested with 10 U of N-glycosidase F for
16 h at 37°C. An additional 3 U of N-glycosidase F
was added, and the digestions were incubated for an additional 2 h.
Isolation of 125-kDa protein from immunoaffinity-purified gCIII
complex.
Seven milligrams of antibody 14-4b (5) was
coupled to 1 ml of CNBr-activated Sepharose 4B (Pharmacia Biotech) as
instructed by the manufacturer. One hundred T150 tissue culture flasks
containing near-confluent cultures of IF cells were infected with HCMV
AD169 at an MOI of approximately 3. At 5 days postinfection, the
infected cells were recovered, pelleted, and resuspended in RIPA buffer supplemented with a protease inhibitor cocktail (PIC) (24)
and 10 mM iodoacetamide for 30 min on ice; insoluble material was removed by centrifugation at 43,000 × g. The clarified
lysate was applied to the 14-4b column and circulated continuously for 16 h by a peristaltic pump. The column was washed with 30 column volumes of RIPA-PIC-iodoacetamide. Bound protein was eluted by 100 mM
glycine (pH 2.5) in RIPA-PIC-iodoacetamide containing 1/10 the amount
of detergents and immediately neutralized by adding a 1/10 volume of 1 M Tris (pH 8.5). Fractions containing the gCIII complex (as judged by
analytical nonreducing SDS-PAGE) were pooled, concentrated with
Centricon filters (Amicon), and subjected to nonreducing SDS-PAGE (6%
gel). To minimize the incidence of oxidants and free radicals, which
may block the N termini of proteins, all preparative acrylamide gels
were allowed to polymerize for 24 h before use, and 0.1 mM
thioglycolate (Sigma) was added to the cathode running buffer of these
preparative gels. The region of the gel containing the gCIII complex
was excised and inserted into the well of a 10% acrylamide gel. This
gel slice was subjected to a secondary reducing SDS-PAGE as described
previously (24). The resultant gel was electrotransferred to
Immobilon-Psq (Millipore) in 25 mM
N-ethylmorpholine (pH to 8.3 with formic acid)-10%
methanol. Transferred proteins were visualized on the membrane by
staining with 0.1% amido black (Sigma) in 40% methanol-10% acetic
acid followed by extensive washes in double-distilled H2O. The membrane was then dried, and appropriate sections were excised for
N-terminal and internal microsequence analysis at the Protein/DNA Technology Center of Rockefeller University (16, 17).
Production of a UL74-specific polyclonal serum.
A portion of
the HCMV UL74 gene (corresponding to the codons for amino acids 32 to
466) was amplified by PCR with Pfu polymerase (Stratagene)
from HCMV AD169 DNA, prepared as described previously (24).
The UL74 PCR product was cloned into plasmid pET28a (Novagen), which
placed the UL74 gene downstream of the coding sequence for a
six-histidine tag. pET28a-UL74 was transformed into Escherichia coli BL21(DE3), and production of recombinant UL74-His protein was
induced by the addition of 1 mM
isopropyl-
-D-thiogalactopyranoside for 2 h. The
insoluble inclusion bodies, containing the recombinant UL74-His
protein, were solubilized in 6 M urea and purified by Ni chelate
chromatography as instructed by the manufacturer (Novagen). Purified
UL74-His protein was injected into a New Zealand White rabbit for
production of an anti-UL74 polyclonal serum.
Computer analyses of protein sequences.
Peptidesort and GAP
analyses of protein sequences were performed with the Genetics Computer
Group (GCG) programs (GCG, Oxford Molecular Group, Inc., Madison, Wis.)
(15).
 |
RESULTS |
Identification of candidate genes encoding the 125-kDa component of
gCIII.
Previously we determined that the 125-kDa protein was
antigenically distinct from gH and gL and was likely the product of an
HCMV gene (24). The diffuse banding pattern of the 125-kDa protein in SDS-PAGE suggested that it was a glycoprotein. To confirm this hypothesis and facilitate genetic identification of the 125-kDa protein, we performed glycosidase digestion of the 125-kDa protein. To
this end, biotinylated gCIII complex was immunoprecipitated and
digested with N-glycosidase F to remove both high-mannose and complex asparagine (N)-linked oligosaccharides. When the blots were
probed with streptavidin-HRP to detect all biotinylated proteins, we
detected in undigested immunoprecipitates from infected cells two
protein species of 125 and 90 kDa, which represent the 125-kDa protein
and gH, respectively (Fig. 1A).
N-Glycosidase F-digested proteins revealed two protein
species of 65 and 84 kDa which likely correspond to deglycosylated
forms of the 125-kDa protein and gH. To confirm that the 90- and 84-kDa
protein species were gH, the blot in Fig. 1A was stripped and probed
with a gH-specific antibody (Fig. 1B). Thus, the 65-kDa protein species
represents 125-kDa protein lacking N-linked chains (the presence of
other posttranslational modifications, such as O-linked
oligosaccharides, was not assessed), confirming, as suggested by its
banding pattern, that it is a glycoprotein containing approximately 60 kDa of N-linked glycosylation on a peptide backbone of 65 kDa or less.
This biochemical profile is similar to that found by Li et al., who
showed that the 125-kDa protein contained both simple and complex
N-linked sugars with a core protein size of approximately 64 kDa
(33). Estimating that a single N-linked oligosaccharide
chain adds between 2 and 4 kDa to the mass of a protein, this analysis
suggested that the gene encoding the 125-kDa glycoprotein would contain 15 to 30 N-linked glycosylation sites, with a primary sequence of ca.
590 amino acids or less. Examination of the HCMV genome revealed only
two ORFs matching these characteristics. The UL74 gene predicts a
protein of 466 amino acids and 18 potential N-linked glycosylation
sites, and the TRL/IRL12 gene predicts a protein of 416 amino acids and
23 potential N-linked glycosylation sites. Both genes were cloned and
expressed as recombinant proteins for use as antigens for the
production of UL74 (this report) and TRL/IRL12-specific antibodies
(data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
N-Glycosidase digestion of the 125-kDa
protein. Mock-infected and HCMV-infected IF cells were surface
biotinylated and immunoprecipitated with antibody 14-4b.
Immunoprecipitated proteins were incubated overnight in the presence or
absence of N-glycosidase, subjected to reducing SDS-PAGE,
and electroblotted to nitrocellulose. (A) The immunoblot was probed
with streptavidin-HRP for detection of biotinylated proteins. (B) The
blot in panel A was stripped and reprobed with an anti-gH antibody
followed by an HRP-conjugated goat anti-mouse antibody. HC,
immunoglobulin heavy chain of the immunoprecipitating antibody.
|
|
Purification and microsequencing of the 125-kDa glycoprotein.
To obtain isolated 125-kDa glycoprotein, the gCIII complex was purified
from HCMV-infected fibroblasts by monoclonal antibody affinity
chromatography. The gCIII complex eluted from the column was excised
from the gel after nonreducing SDS-PAGE, subjected to a second reducing
SDS-PAGE, and then transferred to an Immobilon membrane in preparation
for microsequence analysis. This procedure resulted in purification and
separation of the three complex components (data not shown). To ensure
that we had isolated the gCIII complex and that our purification
methodology was not inherently detrimental to subsequent microsequence
analysis, the portion of the membrane containing the protein
corresponding to gH was initially subjected to N-terminal
microsequencing (17). Microsequencing of this sample yielded
the amino acid sequence XXEALDPHAFHLLLN, which corresponds to amino
acids 32 (E) to 44 (N) of gH. This sequence is ca. 14 amino acids
downstream of the NH3 terminus predicted after cleavage of
the proposed signal peptide (amino acids 1 to 18) (13). This
result suggests that the actual signal peptide is longer than predicted
or that the N terminus of gH is proteolytically processed
posttranslationally. Similar analysis of the 125-kDa glycoprotein
indicated that it was N-terminally blocked. To microsequence an
internally derived peptide, the 125-kDa glycoprotein was digested with
endoproteinase Lys-C and the resultant peptides were purified by
high-pressure liquid chromatography (16). Sequence from a single purified peptide yielded the unambiguous amino acid sequence LYVGPTK. A FASTA database search with this peptide sequence
revealed an exact match to amino acids 189 to 195 of the predicted
product of the HCMV UL74 gene (9) (Fig.
2B), one of the candidate genes identified by glycosidase analysis of the 125-kDa glycoprotein.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 2.
(A) Amino acid sequence of the predicted product of the
HCMV UL74 gene. The sequence matching the internal peptide sequence
derived from the 125-kDa glycoprotein is boxed in black. The
hydrophobic domain is boxed, and potential N-linked glycosylation sites
are underlined. The two potential heparin-binding sequences are
underlined with a dashed line. Numbers on the right denote amino acid
residues. (B) Kyte-Doolittle hydropathy analysis of the UL74 amino acid
sequence. Areas above and below the line denote hydrophilic and
hydrophobic domains, respectively. The scale above the line graph
indicates the amino acid residue.
|
|
Predicted features of the HCMV UL74 gene product.
The UL74
gene encodes a 466-amino-acid protein with a calculated polypeptide
backbone of 54.2 kDa (Fig. 2a). Kyte-Doolittle hydropathy analysis
(31) (Fig. 2B) revealed a hydrophobic sequence near the N
terminus (amino acids 14 to 30) that may serve as a signal sequence. No
other significant hydrophobic sequences that could potentially act as
membrane-spanning domains were detected. Thus, the UL74 glycoprotein
either is soluble and membrane associated via its interaction with gH
or is a type II transmembrane protein since the hydrophobic domain is
inset 14 amino acids from the initiator methionine. These possibilities
are under investigation. The primary amino acid sequence contains 18 potential N-linked glycosylation sites. There are two additional
potential N-linked glycosylation sites within the UL74 primary
sequence, but these are followed by proline residues and thus cannot
serve as sites of oligosaccharide addition (3). There is
also a clustering of serine and threonine residues between amino acids
271 and 337, suggesting potential O-linked glycosylation. The UL74 gene
product is predicted to be a basic protein, based on an isoelectric
point of 10.3, calculated by Peptidesort in the GCG package
(15). Interestingly, a number of the basic lysine and
arginine residues present in the UL74 sequence are concentrated into
two stretches of amino acids (between residues 245 and 270) which are
similar to consensus heparin-binding sequences (6) (Fig.
2B). The UL74 sequence also contains six cysteine residues (one is in
the predicted hydrophobic sequence) which are likely important for
disulfide bonding. Five of the six cysteine residues reside in the
N-terminal half of the sequence.
A nomenclature for HCMV gene products was established in 1993 (
49). Genes encoding glycoproteins are given a "gp"
designation
along with the corresponding ORF; thus, the UL74 gene
product
would be designated gpUL74. To maintain consistency with the
naming
of other herpesvirus envelope glycoproteins, we chose to also
designate the protein with a "g" preceding a capital letter. Since
the last herpesvirus glycoprotein to be named was gN (
2,
26),
we have designated the UL74 glycoprotein as glycoprotein O
(gO).
Characterization of gO in HCMV-infected IF cells.
Antibodies
produced to a recombinant form of UL74 (gO) were analyzed in immunoblot
analysis of HCMV-infected cell lysates (Fig.
3A). The gO antibody specifically reacted
with a protein species migrating broadly between 100 and 125 kDa; this
species apparently comprises several constituents that may be
attributable to processing intermediates or alternates. Pulse-chase
experiments are required to determine the relationships between the
various forms (25). The gO-immunoreactive species first
became apparent at 48 h postinfection and reached maximum levels
at between 72 and 96 h postinfection (Fig. 3A). Additionally, the
other gCIII glycoprotein components, gH and gL, were expressed with
similar kinetics as gO (Fig. 3B and C). This time course of expression of gO, gH, and gL is consistent with the expression of viral structural proteins, which are usually expressed at maximum levels at late times
during infection.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 3.
Time course of expression of gO, gH, and gL. IF cells
were infected with HCMV (MOI of 3) or mock infected and then lysed at
24-h intervals postinfection as indicated above the lanes. Lysates were
resolved by reducing SDS-PAGE and electrotransferred, and the blots
were reacted with anti-gO antibody (A), anti-gH antibody AP865 (B) or
anti-gL antibody 26388 (C).
|
|
gO is present in purified HCMV virions.
Since the 125-kDa
glycoprotein is part of the mature gCIII complex found in virions, gO
is predicted to be present in purified, banded viral particles. The
presence of gO in the mature viral particle was verified by
immunoblotting purified HCMV virions with the gO antibody. Figure
4 shows that the gO antibody was specifically reactive with a 125-kDa species which is consistent in
size and migration pattern with the 125-kDa glycoprotein component of
gCIII. The gO antibody also reacted with an approximately 100-kDa species, which is similar in size to the 100-kDa form of gO present in
infected cells (25). This result suggests that alternatively processed forms of gO may be present in mature virions; experiments to
examine this possibility are under way.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 4.
Immunoblots of purified HCMV virions. Gradient-purified
virions were lysed in reducing SDS-PAGE sample buffer, resolved by
SDS-PAGE, and electrotransferred to nitrocellulose. The blots was
probed with either preimmune serum (as a control) or anti-gO antibody
(ab).
|
|
The gO antibody immunoprecipitates the 240-kDa gCIII complex and
recognizes the 125-kDa glycoprotein component of gCIII.
To confirm
that gO was the 125-kDa third component of the gCIII complex, the gO
antibody was used in immunoprecipitations of lysates of radiolabeled
HCMV-infected IF cells. As shown in Fig.
5A, the gO antibody immunoprecipitated a
240-kDa species which comigrates with the authentic gCIII complex
(24). To verify that the 240-kDa species immunoprecipitated
by the gO antibody is the gCIII complex, the section of the dried gel
containing the 240-kDa species was excised, reduced, and subjected to a
subsequent SDS-PAGE; as a control, the 240-kDa gCIII complex
immunoprecipitated by antibody 14-4b was also excised and reduced.
Figure 5B shows that reduction of the 240-kDa species
immunoprecipitated by the gO antibody yielded three proteins, one of
approximately 125 kDa, one of 90 kDa, and a doublet at approximately 36 kDa, which represent gO, gH, and gL, respectively. An identical profile
was seen upon reduction of the gCIII complex immunoprecipitated by
antibody 14-4b (Fig. 5B). As further confirmation that the 125-kDa
glycoprotein represented gO, duplicates of the excised and reduced
samples from Fig. 5B were immunoblotted with either the gO antibody or a gH antibody. Figure 5C shows that the 125-kDa glycoprotein derived from either immunoprecipitate was detected with the gO antibody. Similarly, the 90-kDa gH protein was detected with the anti-gH antibodies from both immunoprecipitates. These data prove that the
125-kDa glycoprotein present in the gCIII envelope complex, which we
have designated gO, is encoded by the UL74 gene.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Immunoprecipitation of the gCIII complex by the gO
antibody. HCMV-infected cells were metabolically labeled with
[35S]Met-Cys, lysed, and immunoprecipitated with either
the anti-gO antibody or anti-gH/gCIII antibody 14-4b. (A) The proteins
immunoprecipitated with the indicated antibodies were resolved by
nonreducing SDS-PAGE. (B) The ~240-kDa species precipitated by either
the anti-gO or anti-gH immunoprecipitation was excised from the dried
gel, reduced, and resolved by a second reducing SDS-PAGE. (C)
Duplicates of the gel in panel B were electrotransferred to
nitrocellulose and probed with the anti-gO antibody or anti-gH antibody
AP865.
|
|
The HCMV gO gene has positional homologs in other
betaherpesviruses.
We examined the genomes of other
herpesviruses for homologs of the HCMV UL74 gene. Interestingly, the
UL74 gene is positioned within the HCMV genome between two blocks of
genes which are conserved in all herpesviruses (9, 39) (Fig.
6A). The conserved gene block upstream of
the UL74 gene includes the UL69 to UL73 (gN homolog) ORFs, and the
conserved gene block downstream of the UL74 gene includes the UL75 (gH)
to UL79 ORFs (9, 39) (Fig. 6A). Examination of the genomes
of closely related betaherpesviruses, including murine cytomegalovirus
(MCMV) (45), human herpesvirus 6A (HHV-6A) (21,
22), HHV-6B (14, 35), and HHV-7 (40), revealed the same organization of genes as in HCMV, with a gO positional homolog gene flanked by the gN gene block and the gH gene
block (Fig. 6B). In the alphaherpesviruses herpes simplex virus type 1 and varicella-zoster virus, and in the gammaherpesviruses Epstein-Barr
virus (EBV) and HHV-8, the genomic organization of the two conserved
blocks of genes is divergent from that in HCMV (9, 39, 48).
If gO positional homolog genes exist in these four herpesviruses, the
gO homolog gene should be found contiguous with either the gH gene or
the gN homolog gene. However, none of the genes contiguous to the gH
and gN genes in these four herpesviruses encodes for a heavily
glycosylated protein with an N-terminal signal sequence and predicted
basic isoelectric point (data not shown). Thus, there do not appear to
be gO positional homolog genes within the alpha- or gammaherpesviruses,
although these herpesviruses may encode glycoproteins which are
analogous to gO in either structure or function. Indeed, it has been
well established that the EBV BZLF2 gene (not a positional homolog of
the HCMV UL74 gene) encodes a glycoprotein, gp42, which is the third
component of the EBV gH-gL complex (34).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 6.
Schematic representation of betaherpesvirus genomes
showing positional homology of the gO genes. Open boxes represent
terminal and internal repeat regions of the genomes; striped boxes
represent the conserved block of genes including the gN homolog; black
boxes represent the gO gene; hatched boxes represent the conserved
block of genes including the gH gene. (A) HCMV genome; (B) MCMV,
HHV-6A, HHV-6B, and HHV-7 genomes.
|
|
Analyses of the amino acid sequences of the HHV-6A, HHV-6B, HHV-7, and
MCMV gO positional homolog genes indicated, on average,
40% similarity
and 20% identity at the amino acid level to HCMV
gO, analyzed by GAP
in the GCG package (
15) (Table
1). This
relatively low level of identity
is not surprising, since low
amino acid identity is often seen between
herpesvirus glycoprotein
homologs. For instance, HCMV gH and HCMV gL
have approximately
27 and 28% amino acid identity, respectively, with
the other betaherpesvirus
gH and gL homologs, as determined by GAP
analysis (
15) (data
not shown). Alignment analyses of the gO
homolog amino acid sequences
to determine regions of similarity did not
reveal any obvious
conserved domains (data not shown). However, the
predicted products
of the gO positional homolog genes do share a number
of biochemical
features (Table
1). The gO homologs are predicted to be
heavily
glycosylated proteins, containing between 7 and 23 potential
N-linked
glycosylation sites (Table
1). The gO homolog amino acid
sequences
also contain clusters of serine and threonine residues,
suggesting
potential O-linked glycosylation, and five to six cysteine
residues
that reside almost exclusively in the N-terminal half of the
predicted
proteins (data not shown). Also, the gO homologs appear to be
basic proteins, having calculated isoelectric points of approximately
10 as estimated by Peptidesort in the GCG package (
15)
(Table
1).
 |
DISCUSSION |
In this communication, we have reported the genetic identity of a
125-kDa HCMV envelope glycoprotein which associates with gH and gL to
form the viral gCIII envelope complex. Through multiple lines of
evidence, we have demonstrated that this 125-kDa glycoprotein component
is the product of the HCMV UL74 gene. First, biochemical characterization of the 125-kDa glycoprotein suggested the HCMV UL74
gene as a potential gene candidate. Second, amino acid microsequence of
a peptide derived from the purified 125-kDa glycoprotein matched a
sequence within the predicted product of the UL74 gene. Third, antibodies specific for UL74 immunoprecipitated the gCIII complex and
recognized the 125-kDa glycoprotein component of gCIII. We have
designated the HCMV UL74 glycoprotein as gO, consistent with the
nomenclature established for herpesvirus glycoproteins.
The finding that the HCMV gO gene has positional homologs that share
predicted biochemical features suggests that other herpesviruses will
be found to contain a third glycoprotein component in their respective
gH-gL complexes. Interestingly, these gO positional homologs appear to
present only in other betaherpesviruses, suggesting that the gO
homologs represent the first-described betaherpesvirus-specific envelope glycoprotein homologs. It remains to be determined if the
alphaherpesviruses encode a protein that is analogous to gO. However,
it has been well established that the EBV glycoprotein gp42 is a third
component of the EBV gH-gL complex (34). Comparisons of gp42
with gO do not reveal any obvious similarities. gp42 is much smaller
(42 versus 125 kDa) and contains considerably less carbohydrate (10 kDa
of N-linked glycosylation versus at least 60), and it does not require
disulfide bonding for association with EBV gH and gL (34).
Examination of the gp42 amino acid sequence does not reveal it to be a
basic protein (calculated isoelectric point of 8.6 [data not shown]).
The only apparent biochemical similarity between gp42 and gO is that
both are predicted to be type II transmembrane proteins
(34). Most likely, comparisons of the functions of gp42 and
gO will indicate the true relatedness of these two glycoproteins.
What role(s) does gO play in HCMV infection? Since no molecular
functions have been assigned to gO, we can only speculate on the
potential functionality(s) of gO. Due to the association of gO with the
gH-gL complex, a crucial participant in the viral fusion machinery
(29, 30, 41), one obvious function of gO could be to
facilitate entry and/or cell-to-cell spread of infection. In
particular, gO may be required strictly for entry into certain specialized cell types. HCMV has been found in association with a
number of diverse cell types in vivo, and it is likely that the virus
can employ different modes of entry to gain access into these divergent
cell types. Such a role for gO would mirror the functionality of EBV
gp42, which has been shown to be required for entry of virus into one
permissive cell type (B cells) but not the other permissive cell type
(epithelial cells) (34, 52). Alternatively, demonstration
that gO has heparin-binding capabilities, as predicted by primary
sequence analysis, could imply a role in attachment or stabilization of
virus prior to fusion. Efforts are under way to assay the specific
molecular functions of gO and of the gH-gO-gL complex in HCMV
infection.
This study highlights an important limitation in HCMV research. There
are 57 potential glycoproteins in the commonly used laboratory strain
AD169 (9) and as many as 70 glycoprotein ORFs in clinical
isolates (7). This unparalleled glycoprotein-coding capacity
supports the hypothesis that HCMV has the potential for functional
compensation and functional redundancy, a phenomenon documented for
herpesvirus envelope proteins, but implies that HCMV also has the
capability for specialized functional roles tailored to replication and
pathogenic features in the biology of HCMV infection. It is noteworthy,
therefore, that few gene products are characterized with respect to
biosynthesis within infected cells and incorporation into the virion.
In conjunction with an unknown number of individual glycoproteins,
there are three major disulfide-linked envelope complexes, each with
implicated functional roles in entry and spread of infection. Prior to
this report, only the gCI complex, which contains a dimer of gB in association with cellular annexin II (4, 23, 43), was
structurally and genetically defined. Here we report a completed
genetic composition of gCIII. The gCII complex, which has a suggested
role in heparin binding, has at least three protein components, only
one of which is mapped to the viral genome (1, 27, 32).
Thus, before the mechanism of viral entry and spread can be fully
elucidated, whether in model, permissive fibroblasts or in biologically
targeted cell types such as monocytes/macrophages, endothelial cells,
and epithelial cells, the composition of the envelope must be defined and the genes encoding the proteins must be identified.
 |
ACKNOWLEDGMENTS |
This study was supported in part by Public Health Service grant
A1-34998. Protein sequence determination was performed by the
Protein/DNA Technology Center of Rockefeller University.
We gratefully acknowledge the members of the Compton lab for their
assistance and expertise in cell scraping.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medical Microbiology and Immunology, 1300 University Ave., MS493,
University of Wisconsin
Madison Medical School, Madison, WI
53706-1532. Phone: (608) 262-1474. Fax: (608) 262-8418. E-mail:
tcompton{at}facstaff.wisc.edu.
 |
REFERENCES |
| 1.
|
Baines, J. D., and B. Roizman.
1993.
The UL10 gene of herpes simplex virus 1 encodes a novel viral glycoprotein, gM, which is present in the virion and in the plasma membrane of infected cells.
J. Virol.
67:1441-1452[Abstract/Free Full Text].
|
| 2.
|
Barnett, B. C.,
A. Dolan,
E. A. R. Telford,
A. J. Davison, and D. J. McGeoch.
1992.
A novel herpes simplex virus gene (UL49A) encodes a putative membrane protein with counterparts in other herpesviruses.
J. Gen. Virol.
73:2167-2171[Abstract/Free Full Text].
|
| 3.
|
Bause, E.
1983.
Structural requirements of N-glycosylation of proteins. Studies with proline peptides as conformational probes.
Biochem. J.
209:331-336[Medline].
|
| 4.
|
Britt, W. J.
1984.
Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus.
Virology
135:369-378[Medline].
|
| 5.
|
Britt, W. J.,
L. Vulger,
E. J. Butfiloski, and E. B. Stephens.
1990.
Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.
J. Virol.
64:1079-1085[Abstract/Free Full Text].
|
| 6.
|
Cardin, A. D., and H. J. R. Weintraub.
1989.
Molecular modeling of protein-glycosaminoglycan interactions.
Arteriosclerosis
9:21-32[Abstract/Free Full Text].
|
| 7.
|
Cha, T.-A.,
E. Tom,
G. W. Kemble,
G. M. Duke,
E. S. Mocarski, and R. R. Spaete.
1996.
Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains.
J. Virol.
70:78-83[Abstract].
|
| 8.
|
Chang, C. P.,
D. H. Vesole,
J. Nelson,
M. B. Oldstone, and M. F. Stinski.
1989.
Identification and expression of a human cytomegalovirus early glycoprotein.
J. Virol.
63:3330-3337[Abstract/Free Full Text].
|
| 9.
|
Chee, M. S.,
A. T. Bankier,
S. Beck,
R. Bohni,
C. M. Brown,
R. Cerny,
T. Horsnell,
C. A. Hutchison III,
T. Kouzarides,
J. A. Martignetti,
E. Preddie,
S. C. Satchwell,
P. Tomlinson,
K. M. Weston, and B. G. Barrell.
1990.
Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169.
Curr. Top. Microbiol. Immunol.
154:125-169[Medline].
|
| 10.
|
Compton, T.
1993.
An immortalized human fibroblast cell line is permissive for human cytomegalovirus infection.
J. Virol.
67:3644-3648[Abstract/Free Full Text].
|
| 11.
|
Compton, T.,
R. R. Nepomuceno, and D. M. Nowlin.
1992.
Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface.
Virology
191:387-395[Medline].
|
| 12.
|
Cranage, M. P.,
T. Kouzarides,
A. T. Bankier,
S. Satchwell,
K. Weston,
P. Tomlinson,
B. Barrell,
H. Hart,
S. E. Bell,
A. C. Minson, et al.
1986.
Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.
EMBO J.
5:3057-3063[Medline].
|
| 13.
|
Cranage, M. P.,
G. L. Smith,
S. E. Bell,
H. Hart,
C. Brown,
A. T. Bankier,
P. Tomlinson,
B. G. Barrell, and T. C. Minson.
1988.
Identification and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H.
J. Virol.
62:1416-1422[Abstract/Free Full Text].
|
| 14.
|
Dambaugh, T. R.,
J. J. O'Brian,
E. D. Anton,
C. A. Greenamoyer,
G. J. Lindquester, and P. E. Pellett.
1996.
Genetic content of a 20.9 kb segment of human herpesvirus 6B strain Z29 spanning the homologs of human herpesvirus 6A genes U40-57 and containing the origin of replication.
Arch. Virol.
142:103-123.
|
| 15.
|
Devereux, J.,
P. Haeberli, and O. Smithies.
1984.
A comprehensive set of sequence analysis programs for the VAX.
Nucleic Acids Res.
12:387-395.
|
| 16.
|
Fernandez, J.,
L. Andrews, and S. M. Mische.
1994.
An improved procedure for enzymatic digestion of polyvinylidene difluoride-bound proteins for internal sequence analysis.
Anal. Biochem.
214:112-117.
|
| 17.
|
Fernandez, J.,
F. Gharahdaghi, and S. M. Mische.
1998.
Routine identification of proteins from sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels or polyvinyl difluoride membranes using matrix assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS).
Electrophoresis
19:1036-1045[Medline].
|
| 18.
|
Forrester, A.,
H. Farrell,
G. Wilkinson,
J. Kaye,
N. Davis-Poynter, and T. Minson.
1992.
Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted.
J. Virol.
66:341-348[Abstract/Free Full Text].
|
| 19.
|
Fuller, A. O., and W. Lee.
1992.
Herpes simplex virus type 1 entry through a cascade of virus-cell interactions requires different roles of gD and gH in penetration.
J. Virol.
66:5002-5012[Abstract/Free Full Text].
|
| 20.
|
Fuller, A. O.,
R. E. Santos, and P. G. Spear.
1989.
Neutralizing antibodies specific for glycoprotein H of herpes simplex virus permit viral attachment to cell but prevent penetration.
J. Virol.
63:3435-3443[Abstract/Free Full Text].
|
| 21.
|
Gompels, U. A.,
A. L. Carss,
N. Sun, and J. R. Arrand.
1992.
Infectivity determinants encoded in a conserved gene block of human herpesvirus-6.
DNA Sequence
3:25-39[Medline].
|
| 22.
|
Gompels, U. A.,
J. Nicholas,
G. Lawrence,
M. Jones,
M. Jones,
B. J. Thomson,
M. E. D. Martin,
S. Efstathiou,
M. Craxton, and H. A. Macaulay.
1995.
The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution.
Virology
209:29-51[Medline].
|
| 23.
|
Gretch, D. R.,
B. Kari,
L. Rasmussen,
R. C. Gehrz, and M. F. Stinski.
1988.
Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus.
J. Virol.
62:875-881[Abstract/Free Full Text].
|
| 24.
|
Huber, M. T., and T. Compton.
1997.
Characterization of a novel third member of the human cytomegalovirus glycoprotein H-glycoprotein L complex.
J. Virol.
71:5391-5398[Abstract].
|
| 25.
| Huber, M. T., and T. Compton. 1998. Unpublished data.
|
| 26.
|
Jons, A.,
H. Granzow,
R. Kuchling, and T. C. Mettenleiter.
1996.
The UL49.5 gene of pseudorabies virus codes for an O-glycosylated structural protein of the viral envelope.
J. Virol.
70:1237-1241[Abstract].
|
| 27.
|
Kari, B.,
W. Li,
J. Cooper,
R. Goertz, and B. Radeke.
1994.
The human cytomegalovirus UL100 gene encodes the gC-II glycoproteins recognized by group 2 monoclonal antibodies.
J. Gen. Virol.
75:3081-3086[Abstract/Free Full Text].
|
| 28.
|
Kaye, J. F.,
G. U. A., and A. C. Minson.
1992.
Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product.
J. Gen. Virol.
73:2693-2698[Abstract/Free Full Text].
|
| 29.
|
Keay, S., and B. Baldwin.
1991.
Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment.
J. Virol.
65:5124-5128[Abstract/Free Full Text].
|
| 30.
|
Keay, S.,
T. C. Merigan, and L. Rasmussen.
1989.
Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus.
Proc. Natl. Acad. Sci. USA
86:10100-10103[Abstract/Free Full Text].
|
| 31.
|
Kyte, J., and R. F. Doolittle.
1982.
A simple method for displaying the hydropathic character of a protein.
J. Mol. Biol.
157:105-132[Medline].
|
| 32.
|
Lehner, R.,
H. Meyer, and M. Mach.
1989.
Identification and characterization of a human cytomegalovirus gene encoding for a membrane protein that is conserved among human herpesviruses.
J. Virol.
63:3792-3800[Abstract/Free Full Text].
|
| 33.
|
Li, L.,
J. A. Nelson, and W. J. Britt.
1997.
Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex.
J. Virol.
71:3090-3097[Abstract].
|
| 34.
|
Li, Q.,
S. M. Turk, and L. M. Hutt-Fletcher.
1995.
The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells.
J. Virol.
69:3987-3994[Abstract].
|
| 35.
|
Lindquester, G. J.,
N. Inoue,
R. D. Allen,
J. W. Castelli,
F. R. Stamey,
T. R. Dambaugh,
J. J. O'Brian,
R. M. Danovich,
N. Frenkel, and P. E. Pellett.
1996.
Restriction endonuclease mapping and molecular cloning of the human herpesvirus 6 variant B strain Z29 genome.
Arch. Virol.
141:367-379[Medline].
|
| 36.
|
Mach, M.,
U. Utz, and B. Fleckenstein.
1986.
Mapping of the major glycoprotein gene of human cytomegalovirus.
J. Gen. Virol.
67:1461-1467[Abstract/Free Full Text].
|
| 37.
|
Margulies, B. J.,
H. Browne, and W. Gibson.
1996.
Identification of the human cytomegalvirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles.
Virology
225:111-125[Medline].
|
| 38.
|
Miller, N., and L. M. Hutt-Fletcher.
1988.
A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment to Epstein-Barr virus.
J. Virol.
62:2366-2372[Abstract/Free Full Text].
|
| 39.
|
Mocarski, E. S., Jr.
1996.
Cytomegaloviruses and their replication, p. 2447-2492.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 40.
|
Nicholas, J.
1996.
Determination and analysis of the complete nucleotide sequence of human herpesvirus 7.
J. Virol.
70:5975-5989[Abstract].
|
| 41.
|
Pachl, C.,
W. S. Probert,
K. M. Hermsen,
F. R. Masiarz,
L. Rasmussen,
T. C. Merigan, and R. R. Spaete.
1989.
The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86.
Virology
169:418-426[Medline].
|
| 42.
|
Peeters, B.,
N. de Wind,
R. Broer,
A. Gielkens, and R. Moormann.
1992.
Glycoprotein H of pseudorabies virus is essential for entry and cell-to-cell spread of the virus.
J. Virol.
66:3888-3892[Abstract/Free Full Text].
|
| 43.
|
Pietropaolo, R. L., and T. Compton.
1997.
Direct interaction between human cytomegalovirus glycoprotein B and cellular annexin II.
J. Virol.
71:9803-9807[Abstract].
|
| 44.
|
Rasmussen, L.,
R. Nelson,
D. Kelsall, and T. Merigan.
1984.
Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus.
Proc. Natl. Acad. Sci. USA
81:876-880[Abstract/Free Full Text].
|
| 45.
|
Rawlinson, W. D.,
H. E. Farrell, and B. G. Barrell.
1996.
Analysis of the complete DNA sequence of murine cytomegalovirus.
J. Virol.
70:8833-8849[Abstract].
|
| 46.
|
Rodriguez, J. E.,
T. Moninger, and C. Grose.
1993.
Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody.
Virology
196:840-844[Medline].
|
| 47.
|
Roop, C.,
L. Hutchinson, and D. C. Johnson.
1993.
A mutant herpes simplex virus type 1 unable to express glycoprotein L cannot enter cells, and its particles lack glycoprotein H.
J. Virol.
67:2285-2297[Abstract/Free Full Text].
|
| 48.
|
Russo, J. J.,
R. A. Bohenzky,
M.-C. Chien,
J. Chien,
M. Yan,
D. Maddalena,
J. P. Parry,
D. Peruzzi,
I. S. Edelman,
Y. Chang, and P. S. Moore.
1996.
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).
Proc. Natl. Acad. Sci. USA
93:14862-14867[Abstract/Free Full Text].
|
| 49.
|
Spaete, R. R.,
R. C. Gehrz, and M. P. Landini.
1994.
Human cytomegalovirus structural proteins.
J. Gen. Virol.
75:3287-3308[Abstract/Free Full Text].
|
| 50.
|
Spaete, R. R.,
K. Perot,
P. I. Scott,
J. A. Nelson,
M. F. Stinski, and C. Pachl.
1993.
Coexpression of truncated human cytomegalovirus gH with the UL115 gene product or the truncated human fibroblast growth factor receptor results in the transport of gH to the cell surface.
Virology
193:853-861[Medline].
|
| 51.
|
Urban, M.,
W. Britt, and M. Mach.
1992.
The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific.
J. Virol.
66:1303-1311[Abstract/Free Full Text].
|
| 52.
|
Wang, X., and L. M. Hutt-Fletcher.
1988.
Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect.
J. Virol.
72:158-163[Abstract/Free Full Text].
|
Journal of Virology, October 1998, p. 8191-8197, Vol. 72, No. 10
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Fan, Q., Lin, E., Spear, P. G.
(2009). Insertional Mutations in Herpes Simplex Virus Type 1 gL Identify Functional Domains for Association with gH and for Membrane Fusion. J. Virol.
83: 11607-11615
[Abstract]
[Full Text]
-
Vanarsdall, A. L., Ryckman, B. J., Chase, M. C., Johnson, D. C.
(2008). Human Cytomegalovirus Glycoproteins gB and gH/gL Mediate Epithelial Cell-Cell Fusion When Expressed either in cis or in trans. J. Virol.
82: 11837-11850
[Abstract]
[Full Text]
-
Schuessler, A., Sampaio, K. L., Sinzger, C.
(2008). Charge Cluster-to-Alanine Scanning of UL128 for Fine Tuning of the Endothelial Cell Tropism of Human Cytomegalovirus. J. Virol.
82: 11239-11246
[Abstract]
[Full Text]
-
Ryckman, B. J., Chase, M. C., Johnson, D. C.
(2008). HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: Evidence for cell type-specific receptors. Proc. Natl. Acad. Sci. USA
105: 14118-14123
[Abstract]
[Full Text]
-
Jiang, X. J., Adler, B., Sampaio, K. L., Digel, M., Jahn, G., Ettischer, N., Stierhof, Y.-D., Scrivano, L., Koszinowski, U., Mach, M., Sinzger, C.
(2008). UL74 of Human Cytomegalovirus Contributes to Virus Release by Promoting Secondary Envelopment of Virions. J. Virol.
82: 2802-2812
[Abstract]
[Full Text]
-
Ryckman, B. J., Rainish, B. L., Chase, M. C., Borton, J. A., Nelson, J. A., Jarvis, M. A., Johnson, D. C.
(2008). Characterization of the Human Cytomegalovirus gH/gL/UL128-131 Complex That Mediates Entry into Epithelial and Endothelial Cells. J. Virol.
82: 60-70
[Abstract]
[Full Text]
-
Patrone, M., Secchi, M., Bonaparte, E., Milanesi, G., Gallina, A.
(2007). Cytomegalovirus UL131-128 Products Promote gB Conformational Transition and gB-gH Interaction during Entry into Endothelial Cells. J. Virol.
81: 11479-11488
[Abstract]
[Full Text]
-
Krzyzaniak, M., Mach, M., Britt, W. J.
(2007). The Cytoplasmic Tail of Glycoprotein M (gpUL100) Expresses Trafficking Signals Required for Human Cytomegalovirus Assembly and Replication. J. Virol.
81: 10316-10328
[Abstract]
[Full Text]
-
Xie, X., Xu, L., Yang, F.
(2006). Proteomic Analysis of the Major Envelope and Nucleocapsid Proteins of White Spot Syndrome Virus. J. Virol.
80: 10615-10623
[Abstract]
[Full Text]
-
Ehlers, B., Dural, G., Marschall, M., Schregel, V., Goltz, M., Hentschke, J.
(2006). Endotheliotropic elephant herpesvirus, the first betaherpesvirus with a thymidine kinase gene.. J. Gen. Virol.
87: 2781-2789
[Abstract]
[Full Text]
-
Gill, M. B., Gillet, L., Colaco, S., May, J. S., de Lima, B. D., Stevenson, P. G.
(2006). Murine gammaherpesvirus-68 glycoprotein H-glycoprotein L complex is a major target for neutralizing monoclonal antibodies. J. Gen. Virol.
87: 1465-1475
[Abstract]
[Full Text]
-
Sadaoka, T., Yamanishi, K., Mori, Y.
(2006). Human herpesvirus 7 U47 gene products are glycoproteins expressed in virions and associate with glycoprotein H.. J. Gen. Virol.
87: 501-508
[Abstract]
[Full Text]
-
Wang, D., Shenk, T.
(2005). Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. USA
102: 18153-18158
[Abstract]
[Full Text]
-
Spaderna, S., Kropff, B., Kodel, Y., Shen, S., Coley, S., Lu, S., Britt, W., Mach, M.
(2005). Deletion of gpUL132, a Structural Component of Human Cytomegalovirus, Results in Impaired Virus Replication in Fibroblasts. J. Virol.
79: 11837-11847
[Abstract]
[Full Text]
-
Kinzler, E. R., Compton, T.
(2005). Characterization of Human Cytomegalovirus Glycoprotein-Induced Cell-Cell Fusion. J. Virol.
79: 7827-7837
[Abstract]
[Full Text]
-
Gianni, T., Menotti, L., Campadelli-Fiume, G.
(2005). A Heptad Repeat in Herpes Simplex Virus 1 gH, Located Downstream of the {alpha}-Helix with Attributes of a Fusion Peptide, Is Critical for Virus Entry and Fusion. J. Virol.
79: 7042-7049
[Abstract]
[Full Text]
-
Gianni, T., Martelli, P. L., Casadio, R., Campadelli-Fiume, G.
(2005). The Ectodomain of Herpes Simplex Virus Glycoprotein H Contains a Membrane {alpha}-Helix with Attributes of an Internal Fusion Peptide, Positionally Conserved in the Herpesviridae Family. J. Virol.
79: 2931-2940
[Abstract]
[Full Text]
-
Ressing, M. E., van Leeuwen, D., Verreck, F. A. W., Keating, S., Gomez, R., Franken, K. L. M. C., Ottenhoff, T. H. M., Spriggs, M., Schumacher, T. N., Hutt-Fletcher, L. M., Rowe, M., Wiertz, E. J. H. J.
(2005). Epstein-Barr Virus gp42 Is Posttranslationally Modified To Produce Soluble gp42 That Mediates HLA Class II Immune Evasion. J. Virol.
79: 841-852
[Abstract]
[Full Text]
-
Varnum, S. M., Streblow, D. N., Monroe, M. E., Smith, P., Auberry, K. J., Pasa-Tolic, L., Wang, D., Camp, D. G. II, Rodland, K., Wiley, S., Britt, W., Shenk, T., Smith, R. D., Nelson, J. A.
(2004). Identification of Proteins in Human Cytomegalovirus (HCMV) Particles: the HCMV Proteome. J. Virol.
78: 10960-10966
[Abstract]
[Full Text]
-
Akkapaiboon, P., Mori, Y., Sadaoka, T., Yonemoto, S., Yamanishi, K.
(2004). Intracellular Processing of Human Herpesvirus 6 Glycoproteins Q1 and Q2 into Tetrameric Complexes Expressed on the Viral Envelope. J. Virol.
78: 7969-7983
[Abstract]
[Full Text]
-
Mori, Y., Akkapaiboon, P., Yonemoto, S., Koike, M., Takemoto, M., Sadaoka, T., Sasamoto, Y., Konishi, S., Uchiyama, Y., Yamanishi, K.
(2004). Discovery of a Second Form of Tripartite Complex Containing gH-gL of Human Herpesvirus 6 and Observations on CD46. J. Virol.
78: 4609-4616
[Abstract]
[Full Text]
-
Murphy, E., Rigoutsos, I., Shibuya, T., Shenk, T. E.
(2003). Reevaluation of human cytomegalovirus coding potential. Proc. Natl. Acad. Sci. USA
100: 13585-13590
[Abstract]
[Full Text]
-
Crump, C. M., Hung, C.-H., Thomas, L., Wan, L., Thomas, G.
(2003). Role of PACS-1 in Trafficking of Human Cytomegalovirus Glycoprotein B and Virus Production. J. Virol.
77: 11105-11113
[Abstract]
[Full Text]
-
Spear, P. G., Longnecker, R.
(2003). Herpesvirus Entry: an Update. J. Virol.
77: 10179-10185
[Full Text]
-
Hansen, S. G., Strelow, L. I., Franchi, D. C., Anders, D. G., Wong, S. W.
(2003). Complete Sequence and Genomic Analysis of Rhesus Cytomegalovirus. J. Virol.
77: 6620-6636
[Abstract]
[Full Text]
-
Mori, Y., Akkapaiboon, P., Yang, X., Yamanishi, K.
(2003). The Human Herpesvirus 6 U100 Gene Product Is the Third Component of the gH-gL Glycoprotein Complex on the Viral Envelope. J. Virol.
77: 2452-2458
[Abstract]
[Full Text]
-
Rasmussen, L., Geissler, A., Cowan, C., Chase, A., Winters, M.
(2002). The Genes Encoding the gCIII Complex of Human Cytomegalovirus Exist in Highly Diverse Combinations in Clinical Isolates. J. Virol.
76: 10841-10848
[Abstract]
[Full Text]
-
Theiler, R. N., Compton, T.
(2002). Distinct Glycoprotein O Complexes Arise in a Post-Golgi Compartment of Cytomegalovirus-Infected Cells. J. Virol.
76: 2890-2898
[Abstract]
[Full Text]
-
Spaderna, S., Blessing, H., Bogner, E., Britt, W., Mach, M.
(2002). Identification of Glycoprotein gpTRL10 as a Structural Component of Human Cytomegalovirus. J. Virol.
76: 1450-1460
[Abstract]
[Full Text]
-
Theiler, R. N., Compton, T.
(2001). Characterization of the Signal Peptide Processing and Membrane Association of Human Cytomegalovirus Glycoprotein O. J. Biol. Chem.
276: 39226-39231
[Abstract]
[Full Text]
-
Bahr, U., Darai, G.
(2001). Analysis and Characterization of the Complete Genome of Tupaia (Tree Shrew) Herpesvirus. J. Virol.
75: 4854-4870
[Abstract]
[Full Text]
-
Mach, M., Kropff, B., Dal Monte, P., Britt, W.
(2000). Complex Formation by Human Cytomegalovirus Glycoproteins M (gpUL100) and N (gpUL73). J. Virol.
74: 11881-11892
[Abstract]
[Full Text]
-
Lake, C. M., Hutt-Fletcher, L. M.
(2000). Epstein-Barr Virus That Lacks Glycoprotein gN Is Impaired in Assembly and Infection. J. Virol.
74: 11162-11172
[Abstract]
[Full Text]
-
Wang, S.-K., Duh, C.-Y., Chang, T.-T.
(2000). Cloning and identification of regulatory gene UL76 of human cytomegalovirus. J. Gen. Virol.
81: 2407-2416
[Abstract]
[Full Text]
-
Hobom, U., Brune, W., Messerle, M., Hahn, G., Koszinowski, U. H.
(2000). Fast Screening Procedures for Random Transposon Libraries of Cloned Herpesvirus Genomes: Mutational Analysis of Human Cytomegalovirus Envelope Glycoprotein Genes. J. Virol.
74: 7720-7729
[Abstract]
[Full Text]
-
Maresová, L., Kutinová, L., Ludvíková, V., Zák, R., Mares, M., Nemecková, S.
(2000). Characterization of interaction of gH and gL glycoproteins of varicella-zoster virus: their processing and trafficking. J. Gen. Virol.
81: 1545-1552
[Abstract]
[Full Text]
-
Dominguez, G., Dambaugh, T. R., Stamey, F. R., Dewhurst, S., Inoue, N., Pellett, P. E.
(1999). Human Herpesvirus 6B Genome Sequence: Coding Content and Comparison with Human Herpesvirus 6A. J. Virol.
73: 8040-8052
[Abstract]
[Full Text]
-
Beisser, P. S., Grauls, G., Bruggeman, C. A., Vink, C.
(1999). Deletion of the R78 G Protein-Coupled Receptor Gene from Rat Cytomegalovirus Results in an Attenuated, Syncytium-Inducing Mutant Strain. J. Virol.
73: 7218-7230
[Abstract]
[Full Text]
-
Chambers, J., Angulo, A., Amaratunga, D., Guo, H., Jiang, Y., Wan, J. S., Bittner, A., Frueh, K., Jackson, M. R., Peterson, P. A., Erlander, M. G., Ghazal, P.
(1999). DNA Microarrays of the Complex Human Cytomegalovirus Genome: Profiling Kinetic Class with Drug Sensitivity of Viral Gene Expression. J. Virol.
73: 5757-5766
[Abstract]
[Full Text]
-
Anderson, R., Gompels, U.
(1999). N- and C-terminal external domains of human herpesvirus-6 glycoprotein H affect a fusion-associated conformation mediated by glycoprotein L binding the N terminus. J. Gen. Virol.
80: 1485-1494
[Abstract]
-
Huber, M. T., Compton, T.
(1999). Intracellular Formation and Processing of the Heterotrimeric gH-gL-gO (gCIII) Glycoprotein Envelope Complex of Human Cytomegalovirus. J. Virol.
73: 3886-3892
[Abstract]
[Full Text]